Nuo Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Apr 1, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 1, 2025
AURXStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
Nuo Therapeutics, Inc.
Consolidated Statements of Changes in Stockholders' Equity
For the Years Ended December 31, 2024 and 2023
| Common Stock | |||||
|---|---|---|---|---|---|
| Shares | Amount (par $0.0001) | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity | |
| Balance, December 31, 2022 | 41,799,016 | 4,180 | 28,951,963 | (26,764,805) | 2,191,338 |
| Share-based compensation expense | - | - | 21,746 | - | 21,746 |
| Issuance of common stock for cash proceeds | 2,422,500 | 244 | 1,997,256 | - | 1,997,500 |
| Net loss | - | - | - | (3,171,436) | (3,171,436) |
| Balance, December 31, 2023 | 44,241,516 | $4,424 | $30,970,965 | $(29,936,241) | $1,039,148 |
| Share-based compensation expense | - | - | 56,652 | - | 56,652 |
| Issuance of common stock for cash proceeds | 2,000,000 | 200 | 1,499,800 | - | 1,500,000 |
| Issuance of common stock for warrant exercise | 270,000 | 27 | 151,173 | - | 151,200 |
| Issuance of common stock for cashless warrant exercise | 86,889 | 9 | (9) | - | - |
| Issuance of common stock for option exercise | 217,709 | 22 | 90,395 | - | 90,417 |
| Net loss | - | - | - | (2,323,705) | (2,323,705) |
| Balance, December 31, 2024 | 46,816,114 | $4,682 | $32,768,976 | $(32,259,946) | $513,712 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.